We advocate for testing SMAD6 variants in PAH patients, particularly those with complex congenital heart defects or unclear cardiovascular abnormalities, as well as PAH patients with craniosynostosis or radial synostosis. The gene discussed is SMAD6; the disease is pulmonary arterial hypertension.